Marc Scheineson comments on the U.S. Food and Drug Administration’s approval of promotional materials highlighting a drug’s novel and generic abuse-deterrent formulation.
In the News
March 30, 2017
The Pink Sheet | Off-Label Opioid Promotion: US FDA 'Does Not Object' To Intranasal Deterrence Data, Egalet Says
Media Contact